555547c000 Hyundai KIA Bushing

555547c000 Hyundai KIA Bushing

Model NO.: ybs-kia-56452
Trademark: CHON/ YOUR BRAND/ NO BRAND
Transport Package: Pallet
Specification: 67mm
Origin: China
HS Code: 870899999
Model NO.: ybs-kia-56452
Trademark: CHON/ YOUR BRAND/ NO BRAND
Transport Package: Pallet
Specification: 67mm
Origin: China
HS Code: 870899999
PRODUCT DETAILS

(FACTORY) suspension system natural rubber parts torque rod bush(DANA long term supplier)

Can produce any rubber parts as your samples and drawings.

About us:

Special manufacturer of heavy truck/bus Torque Rod, Torque Rod Bush, Drive shaft, Axle parts, Differential Assy,  Brake Drum and Wheel Hub.

Products range:

     ◊ European trucks: Mercedes benz, Volvo, Scania, MAN, DAF, RVI, Iveco.

     ◊ Chinese trucks: Steyr, Howo, Faw, Dongdeng, Shanxi, EQ153, Foton, CAMC, Kinglong, Golden Dragon, Yutong.

     ◊ Japanese trucks: Hino, Nissan,Mitsubish, Isuzu.

      ◊ Korean trucks: Hyundai, KIA

555547c000 Hyundai KIA Bushing
Factory Overview

555547c000 Hyundai KIA Bushing
Contact info:
555547c000 Hyundai KIA Bushing


Welcome to visit us!!!! PRODUCT DETAILS

(FACTORY) suspension system natural rubber parts torque rod bush(DANA long term supplier)

Can produce any rubber parts as your samples and drawings.

About us:

Special manufacturer of heavy truck/bus Torque Rod, Torque Rod Bush, Drive shaft, Axle parts, Differential Assy,  Brake Drum and Wheel Hub.

Products range:

     ◊ European trucks: Mercedes benz, Volvo, Scania, MAN, DAF, RVI, Iveco.

     ◊ Chinese trucks: Steyr, Howo, Faw, Dongdeng, Shanxi, EQ153, Foton, CAMC, Kinglong, Golden Dragon, Yutong.

     ◊ Japanese trucks: Hino, Nissan,Mitsubish, Isuzu.

      ◊ Korean trucks: Hyundai, KIA

555547c000 Hyundai KIA Bushing
Factory Overview

555547c000 Hyundai KIA Bushing
Contact info:
555547c000 Hyundai KIA Bushing


Welcome to visit us!!!!

Vemurafenib API

Vemurafenib is an orally bioavailable, ATP-competitive, small-molecule inhibitor of BRAF(V600E) kinase with potential antineoplastic activity. Vemurafenib selectively binds to the ATP-binding site of BRAF(V600E) kinase and inhibits its activity, which may result in an inhibition of an over-activated MAPK signaling pathway downstream in BRAF(V600E) kinase-expressing tumor cells and a reduction in tumor cell proliferation. Approximately 90% of BRAF gene mutations involve a valine-to-glutamic acid mutation at residue 600 (V600E); the oncogene protein product, BRAF(V600E) kinase, exhibits a markedly elevated activity that over-activates the MAPK signaling pathway. The BRAF(V600E) gene mutation has been found to occur in approximately 60% of melanomas, and in about 8% of all solid tumors, including melanoma, colorectal, thyroid and other cancers.

Vemurafenib is a selective inhibitor of BRAF kinase that is used in the therapy of patients with metastatic and advanced malignant melanoma. Vemurafenib therapy is commonly associated with transient elevations in serum aminotransferase during therapy and has been linked to rare, but occasionally severe cases of clinically apparent acute liver injury.


China Vemurafenib Api,Vemurafenib Cas 1029872-54-5 manufacturers, welcome Vemurafenib Api Cas 1029872-54-5,Vemurafenib Indications purchasers from worldwide to visit our site.

Vemurafenib Api,Vemurafenib Cas 1029872-54-5,Vemurafenib Api Cas 1029872-54-5,Vemurafenib Indications

 Shandong Haohong Biotechnology Co., Ltd. , https://www.haohongpharma.com